Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sulfur Hexafluoride Microspheres Clear all
Completed Early Phase 1 Interventional

Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis

NCT03407001
View directory record Official record
Conditions
Cirrhosis
Interventions
Contrast-Enhanced Ultrasound, Sulfur Hexafluoride Lipid Microspheres, Ultrasound
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 25, 2026, 10:18 AM EDT
Recruiting Phase 2 Interventional

Y-90 Treatment Response Using Transarterial Radioembolization

NCT07145801
View directory record Official record
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 25, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

NCT03907657
View directory record Official record
Conditions
Von-Hippel Lindau, Kidney Disease, Chronic
Interventions
Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
16 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 25, 2026, 10:18 AM EDT
Recruiting Phase 3 Interventional

Lumason® Infusion vs. Bolus Administrations

NCT06400004
View directory record Official record
Conditions
Heart Diseases
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON], Lumason
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
West Hills, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 25, 2026, 10:18 AM EDT
Recruiting Phase 1 Interventional

NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors

NCT07664176
View directory record Official record
Conditions
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas, Medulloblastoma Recurrent, Ependymoma Recurrent, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, Brain Tumor Recurrent
Interventions
NeuroNavigation-Guided Focused Ultrasound (NgFUS), Lumason, Nivolumab
Device · Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 25, 2026, 10:18 AM EDT
Withdrawn Phase 4 Interventional

Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients

NCT03963999
View directory record Official record
Conditions
Sinusoidal Obstruction Syndrome, Veno Occlusive Disease, Hepatic, Bone Marrow Transplant Complications, Stem Cell Transplant Complications
Interventions
Ultrasound Elastography, Contrast Enhanced Ultrasound (CEUS)
Diagnostic Test · Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Month to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 25, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions

NCT03652636
View directory record Official record
Conditions
Hepatic Disease
Interventions
Sulfur Hexafluoride Microspheres
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 25, 2026, 10:18 AM EDT
Recruiting Phase 2 Interventional

CEUS Evaluation of Hydrocephalus in Neonates and Infants

NCT06693752
View directory record Official record
Conditions
Hydrocephalus in Infants, Hydrocephalus Acquired
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Minute to 18 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 25, 2026, 10:18 AM EDT
Recruiting Phase 2 Interventional

SHAPE of Portal Hypertension in Children

NCT04720456
View directory record Official record
Conditions
Hypertension, Portal
Interventions
SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles), SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 25, 2026, 10:18 AM EDT
Withdrawn Not applicable Interventional

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

NCT03300401
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging, Positron Emission Tomography, Computed Tomography, Yttrium-90 (90Y)
Drug · Device · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 25, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

NCT04021238
View directory record Official record
Conditions
Kidney Cancer
Interventions
Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 25, 2026, 10:18 AM EDT
Recruiting Phase 2 Interventional

Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

NCT05641935
View directory record Official record
Conditions
Recurrent Renal Cell Carcinoma, Renal Cell Carcinoma
Interventions
Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Computed Tomography, Magnetic Resonance Imaging, Electronic Health Record Review
Drug · Procedure · Other
Lead sponsor
john eisenbrey
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 25, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

The Role of Contrast Enhanced Ultrasound in Appendicitis

NCT03687502
View directory record Official record
Conditions
Acute Appendicitis
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 25, 2026, 10:18 AM EDT
Terminated Phase 3 Interventional Results available

CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis

NCT03549507
View directory record Official record
Conditions
Necrotizing Enterocolitis of Newborn, Bowel Ischemic
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 18 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 25, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

Contrast Enhanced Ultrasound in COVID-19

NCT04640038
View directory record Official record
Conditions
Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C)
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Minute to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 25, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

CEUS Evaluation of Hypoxic Ischemic Injury

NCT03549520
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Brain Ischemia Hypoxia
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Minute to 18 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 25, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142

NCT02552238
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Lumason
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Santa Ana, California • Wilmington, Delaware • Homestead, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 25, 2026, 10:18 AM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography

NCT02282163
View directory record Official record
Conditions
Heart Disease
Interventions
sulphur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
9 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
St Louis, Missouri • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 25, 2026, 10:18 AM EDT
Withdrawn Phase 1 Interventional

Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis

NCT03295656
View directory record Official record
Conditions
Appendicitis Acute
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 25, 2026, 10:18 AM EDT
Terminated Phase 1 Interventional

Contrast-Enhanced Ultrasound for Kidney Transplant

NCT02911714
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Lumason Contrast-Enhanced Ultrasound
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 25, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141

NCT02522481
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Lumason
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Tucson, Arizona • La Jolla, California • West Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 25, 2026, 10:18 AM EDT
Recruiting Phase 1 Interventional

Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses

NCT06171607
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Contrast-Enhanced Ultrasound, Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres
Procedure · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 25, 2026, 10:18 AM EDT
Not yet recruiting Phase 1 Interventional

Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)

NCT03653702
View directory record Official record
Conditions
Vesico-Ureteral Reflux
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 35 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 25, 2026, 10:18 AM EDT
Recruiting Phase 4 Interventional

CEUS for Blunt Abdominal Trauma in Children

NCT03490929
View directory record Official record
Conditions
Trauma Abdomen
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON], contrast-enhanced ultrasound
Drug · Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 25, 2026, 10:18 AM EDT